![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
646kB |
Preview |
PDF (Supplementary Information)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB |
| Item Type: | Article |
|---|---|
| Title: | Therapy switches in fingolimod-treated patients with multiple sclerosis: long-term experience from the German MS Registry |
| Creators Name: | Frahm, N., Fneish, F., Ellenberger, D., Flachenecker, P., Paul, F., Warnke, C., Kleinschnitz, C., Parciak, T., Krefting, D., Hellwig, K., Haas, J., Rommer, P.S., Stahmann, A. and Zettl, U.K. |
| Abstract: | INTRODUCTIONS: Therapy switches in patients with multiple sclerosis (MS) receiving treatment with fingolimod occur frequently in clinical practice but are not well represented in real-world data. The aim of this study was to identify and characterize treatment switches and reveal sociodemographic/clinical changes over time in fingolimod-treated people with MS (PwMS). METHODS: Data on 2536 fingolimod-treated PwMS extracted from the German MS Registry during different time periods were analyzed (2010-2019). RESULTS: Overall, 28.3% of PwMS were treatment-naïve before fingolimod initiation. Interferon beta (30.7%) was the most common pre-fingolimod treatment. Ocrelizumab (19.8%) was the most frequent subsequent treatment in the 944 patients on fingolimod who switched. Between 2010 and 2019, median disease duration at fingolimod initiation decreased from 8.5 to 7.1 years (p < 0.001), and patients taking fingolimod for ≥ 1 year after treatment initiation decreased from 89.6 to 80.5% (p < 0.001). Females (p < 0.001) and young patients (p = 0.003) showed a shorter time on fingolimod. The most frequent reason for switching was disease activity (relapse/MRI) despite treatment. The annualized relapse rate increased from 0.37 in patients on fingolimod to 0.47 after treatment cessation, decreasing to 0.19 after treatment with a subsequent disease-modifying drug (DMD) was initiated. CONCLUSION: Treatment switches from fingolimod to subsequent DMDs currently occur after shorter treatment durations than 10 years ago, possibly due to the growing treatment spectrum. Planning adequate washout periods is essential and should be done on an individualized basis. |
| Keywords: | Multiple Sclerosis, Fingolimod, Treatment Switches, Rebound, Disease-Modifying Drug |
| Source: | Neurology and Therapy |
| ISSN: | 2193-8253 |
| Publisher: | Springer |
| Volume: | 11 |
| Number: | 1 |
| Page Range: | 319–336 |
| Date: | March 2022 |
| Official Publication: | https://doi.org/10.1007/s40120-021-00320-w |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
